AstraZeneca PLC (AZN)

33.94
0.16 0.47
NYSE : Health Care
Prev Close 33.78
Open 33.95
Day Low/High 33.71 / 33.99
52 Wk Low/High 25.55 / 35.60
Volume 4.07M
Avg Volume 4.45M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 85.71B
EPS 1.40
P/E Ratio 15.18
Div & Yield 1.90 (5.60%)

Latest News

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

We're Downgrading Snap-On

Despite earnings beat, company is in a 'battleground.'

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

AstraZeneca Shares Top FTSE 100 After Drugmaker Says CEO Will Host Late-July Earnings Call

AstraZeneca Shares Top FTSE 100 After Drugmaker Says CEO Will Host Late-July Earnings Call

AstraZeneca shares rose after the group said its CEO would host an earnings call later this month following speculation he was to take up a similar role Teva Pharmaceuticals.

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

Rumors swirled that Pascal Soriot would leave for rival Teva Pharmaceuticals.

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Neither company has confirmed Pascal Soriot's move.

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European benchmarks held gains much of Thursday.

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca shares dropped in the first hours of trading Thursday after it was reported that Teva Pharmaceuticals was courting its CEO.

Teva Stock Jumps as New CEO Expected to Be Named

Teva Stock Jumps as New CEO Expected to Be Named

AstraZeneca CEO Pascal Sorio will reportedly take over at Teva.

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Europe Stocks Slip as Economic Data and Politics Return to the Fore

Europe Stocks Slip as Economic Data and Politics Return to the Fore

The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.

Europe Mixed at Close After Day of Pressure

Europe Mixed at Close After Day of Pressure

Commodity markets, economic growth and the potential for a broad tightening of monetary policy in the developed world over the coming quarters recaptured investors' attention Thursday.

Europe Benchmarks Rebound as Central Bank Actions Fall by the Wayside

Europe Benchmarks Rebound as Central Bank Actions Fall by the Wayside

European stocks rebounded with a bang Friday as recent central bank actions fell by the wayside and markets took heart from the latest bailout deal between Greece and the EU.

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

AstraZeneca Presents New Data Underpinning Safety Profile And Real-World CV Outcomes Of Farxiga At ADA 2017

AstraZeneca presented new data at the American Diabetes Association's (ADA) 77th Scientific Sessions underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

AstraZeneca To Present Scientific Advances In Cardiovascular And Metabolic Diseases At 2017 ADA Scientific Sessions

AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company's Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga...

AstraZeneca Presents Tagrisso® (osimertinib) Data In Patients With EGFR T790M-Mutation Positive Lung Cancer And Central Nervous System Metastases

AstraZeneca today reported further evidence that Tagrisso ® (osimertinib), the potential new standard of care for patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small...

European Stocks Slip as Banks, Economic Data Weigh

European Stocks Slip as Banks, Economic Data Weigh

European stocks slipped Monday as investors digested the latest terror attack in the U.K., continued concern over Spanish banks and a series of poorer-than-expected economic bulletins.

AstraZeneca's Big Bet on Oncology May Finally Pay Off

AstraZeneca's Big Bet on Oncology May Finally Pay Off

AstraZeneca plc said Monday that one of its new drugs has proven more effective than chemotherapy in treating a certain type of breast cancer.

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.

LYNPARZA™ (olaparib) Significantly Reduces The Risk Of Disease Worsening Or Death In Patients With BRCA-Mutated Metastatic Breast Cancer

AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with...

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

AstraZeneca Delivers New Data On Expanding Portfolio Of Cancer Medicines At 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company's science-led strategy for transformational cancer medicine development at...